Estrogen Receptor Ligands. II. Discovery of Benzoxathiins as Potent, Selective Estrogen Receptor alpha Modulators.
Kim, S., Wu, J.Y., Birzin, E.T., Frisch, K., Chan, W., Pai, L.Y., Yang, Y.T., Mosley, R.T., Fitzgerald, P.M., Sharma, N., Dahllund, J., Thorsell, A.G., DiNinno, F., Rohrer, S.P., Schaeffer, J.M., Hammond, M.L.(2004) J Med Chem 47: 2171-2175
- PubMed: 15084115 
- DOI: https://doi.org/10.1021/jm034243o
- Primary Citation of Related Structures:  
1SJ0 - PubMed Abstract: 
The discovery and synthesis of dihydrobenzoxathiins as potent, ERalpha subtype selective ligands are described. The most active analogue, 4-D, was found to be 50-fold selective in a competitive binding assay and 100-fold selective in a transactivation assay in HEK-293 cells. The alpha selectivity was postulated to lie in the interaction of the sulfur atom of the benzoxathiin ring with the two discriminating residues in the binding pocket of the receptor isoforms.
Organizational Affiliation: 
Department of Medicinal Chemistry, Atherosclerosis and Endocrinology, Merck Research Laboratories, P.O. Box 2000, 800-B109 Rahway, New Jersey 07065, USA. Seongkon_kim@merck.com